Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...